Clinical Trial Update: GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA) [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating lixisenatide added to basal insulin (with or without sulfonylurea) in type 2 diabetes for glycemic control and safety. Results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Adlyxin (lixisenatide)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2016-10-11